Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 4:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2521–2544 of 4,249 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Study Product Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis

NCT02616601
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Generic Fluorouracil Cream, Carac® (Fluorouracil) Cream, Vehicle Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
17
States / cities
Fremont, California • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Nov 10, 2026, 4:14 PM EST
Withdrawn Phase 2 Interventional

Post-Operative Steroids After Sleep Surgery

NCT06818981
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
8mg dexamethasone
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 10, 2026, 4:14 PM EST
Completed Not applicable Interventional

Study of the Safety and Tolerability of AXA1665 in Subjects With Mild and Moderate Hepatic Insufficiency

NCT04147936
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
AXA1665, Placebo
Dietary Supplement
Lead sponsor
Axcella Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Montclair, California • Tustin, California • Miami Lakes, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2020 · Synced Nov 10, 2026, 4:14 PM EST
Completed Early Phase 1 Interventional Results available

Sildenafil To Prevent Clot

NCT03199612
View directory record Official record
Conditions
Thrombosis, Hemolysis
Interventions
Sildenafil, Placebo Oral Tablet
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Nov 10, 2026, 4:14 PM EST
Terminated Phase 3 Interventional Results available

Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

NCT01200992
View directory record Official record
Conditions
Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ, Mycobacterium
Interventions
EN3348, Mitomycin C
Biological
Lead sponsor
Bioniche Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
56
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Nov 10, 2026, 4:14 PM EST
Completed Phase 3 Interventional Results available

A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis

NCT02349295
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Placebo, Ixekizumab 80 mg Q4W, Ixekizumab 80 mg Q2W
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
59
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Nov 10, 2026, 4:14 PM EST
Terminated Phase 3 Interventional

Apnex Clinical Study of the Hypoglossal Nerve Stimulation (HGNS®) System to Treat Obstructive Sleep Apnea

NCT01446601
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Hypoglossal Nerve Stimulation (HGNS) System (Apnex Medical )
Device
Lead sponsor
Apnex Medical, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
12
States / cities
Lenexa, Kansas • Topeka, Kansas • Louisville, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Nov 10, 2026, 4:14 PM EST
Not yet recruiting Phase 3 Interventional

Optimal Timing of Ketamine Initiation for SCD Pain

NCT07450430
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Crisis
Interventions
Ketamine hydrochloride injection, Placebo
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years to 24 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Nov 10, 2026, 4:14 PM EST
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer

NCT00028964
View directory record Official record
Conditions
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Interventions
Chinese herbs, cyclophosphamide, doxorubicin hydrochloride, adjuvant therapy
Dietary Supplement · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Nov 10, 2026, 4:14 PM EST
Completed Phase 1Phase 2 Interventional Results available

IL1-TRAP, Rilonacept, in Systemic Sclerosis

NCT01538719
View directory record Official record
Conditions
Scleroderma, Systemic Sclerosis, Diffuse Scleroderma, Diffuse Systemic Sclerosis
Interventions
Rilonacept, Placebo
Drug · Other
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Nov 10, 2026, 4:14 PM EST
Withdrawn Phase 2 Interventional

Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine

NCT02246075
View directory record Official record
Conditions
Alzheimer's Disease, Dementia, Cognition
Interventions
EVP-6124
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
55 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
2
States / cities
Delray Beach, Florida • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Nov 10, 2026, 4:14 PM EST
Completed Phase 2 Interventional Results available

A Long-Term, Placebo-Controlled X-Ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects With Osteoarthritis of the Knee

NCT00565812
View directory record Official record
Conditions
Osteoarthritis
Interventions
SD-6010, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 99 Years
Enrollment
1,457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
120
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2016 · Synced Nov 10, 2026, 4:14 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Evaluation of One-Shot Vision Differential Diagnosis (OSVDE) and Multi-Step Conversational Non-Inferiority (MSCNE) in AI Medical Interviewing

NCT07470463
View directory record Official record
Conditions
Differential Diagnosis, Diagnostic Accuracy
Interventions
AI Diagnostic System (AIMD.1)
Diagnostic Test
Lead sponsor
Magic Health Inc. (d.b.a. Nolla Health)
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Nov 10, 2026, 4:14 PM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses

NCT02120898
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Imiquimod, Zyclara®, Vehicle Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
27
States / cities
Birmingham, Alabama • Fremont, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Nov 10, 2026, 4:14 PM EST
Completed Not applicable Interventional Results available

CAMS Relational Agent System (CAMS-RAS) for Suicide Prevention

NCT03584386
View directory record Official record
Conditions
Suicide
Interventions
Jaspr, Jaspr-at-Home (JAH)
Device
Lead sponsor
Evidence-Based Practice Institute, Seattle, WA
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Nov 10, 2026, 4:14 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together

NCT00352066
View directory record Official record
Conditions
HIV Infection
Interventions
apricitabine
Drug
Lead sponsor
Avexa
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Nov 10, 2026, 4:14 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Characterization of Biomarkers of Tobacco Exposure, Urge-to-Smoke Following Exclusive and Dual Ad Lib Use of Electronic Cigarettes

NCT02385227
View directory record Official record
Conditions
Cigarette Smoking
Interventions
Exclusive blu™ e-cigarette A1, Exclusive blu™ e-cigarette A2, Exclusive blu™ e-cigarette A3, Dual blu™ e-cigarette and usual brand B1, Dual blu™ e-cigarette and usual brand B2, Dual blu™ e-cigarette and usual brand B3, Nicotine product cessation C
Other
Lead sponsor
Lorillard Tobacco Company
Industry
Eligibility
21 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Nov 10, 2026, 4:14 PM EST
Not yet recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.

NCT06731075
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
ORMD-0801 8 mg, Placebo capsule, ORMD-0801 16 mg
Drug · Other
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
50 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Nov 10, 2026, 4:14 PM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study

NCT01194830
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Linagliptin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
93
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 76 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Nov 10, 2026, 4:14 PM EST
Completed Not applicable Interventional Results available

ECAP-controlled, Closed-loop Stimulation to Treat Chronic Trunk and/or Limb Pain (ECAP)

NCT04319887
View directory record Official record
Conditions
Chronic Pain, Back Pain, Pain
Interventions
Evoke Spinal Cord Stimulation (SCS) System
Device
Lead sponsor
Saluda Medical Pty Ltd
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
22
States / cities
Little Rock, Arkansas • Carlsbad, California • Santa Rosa, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Nov 10, 2026, 4:14 PM EST
Withdrawn Phase 4 Interventional

A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression

NCT02719392
View directory record Official record
Conditions
Bipolar Disorder, Bipolar Depression
Interventions
N-acetylcysteine, Minocycline, Placebo
Dietary Supplement · Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Nov 10, 2026, 4:14 PM EST
Not listed Phase 2 Interventional Accepts healthy volunteers

Machine Learning Sepsis Alert Notification Using Clinical Data

NCT04005001
View directory record Official record
Conditions
Sepsis, Severe Sepsis, Septic Shock
Interventions
HindSight, InSight
Other
Lead sponsor
Dascena
Industry
Eligibility
18 Years and older
Enrollment
37,986 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Springfield, Massachusetts • Camden, New Jersey • Cape May, New Jersey
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Nov 10, 2026, 4:14 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Effects of CC-99677 on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Participants

NCT04718636
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Oral Contraceptive (Ortho Tri-Cyclen or its generic equivalent), CC-99677
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
3
States / cities
Miami, Florida • Marlton, New Jersey • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Nov 10, 2026, 4:14 PM EST
Completed Phase 2 Interventional

Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function

NCT01280344
View directory record Official record
Conditions
Gastrointestinal Dysmotility
Interventions
Saline Solution for Injection, Ipamorelin
Drug
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
45
States / cities
Florence, Alabama • Sheffield, Alabama • Fountain Valley, California + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Nov 10, 2026, 4:14 PM EST